A paradigm shift in the intention-to-transplant children with biliary atresia: Outcomes of 101 cases and a review of the literature.


Journal

Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574

Informations de publication

Date de publication:
11 2019
Historique:
received: 27 03 2019
revised: 14 07 2019
accepted: 23 07 2019
pubmed: 15 8 2019
medline: 20 9 2020
entrez: 15 8 2019
Statut: ppublish

Résumé

For children with BA who do not benefit from Kasai surgery, the only therapeutic option is liver replacement and transplantation. The very decision to proceed for transplantation is a crucial point in time because it is the first step toward the preparation for the transplantation. The former time point is defined in this analysis as "intent-to-transplant" care pathway. In the life of every BA candidate for liver replacement, this point in time varies and mostly depends on the decision of their primary caring teams-about when to switch from supportive care to transplant, and thus to refer to a transplant center. This intent-to-transplant analysis of a series of 101 consecutive infants that were referred to a single transplant team showed that excellent overall outcome (97% survival) has been achieved overall. However, three deaths occurred that were clearly related to a late referral. This analysis and recent observations from other centers strongly support that the timing for referring these children to a transplant center and/or deciding to list them on the waiting list is currently too late and should be anticipated to what it is currently. This paradigm shift in the intention-to-transplant children is likely necessary for giving a better chance to an increased number of children and impacts positively on the general outcome. Networking and defining new tools for a rapid recognition of the infants who need early transplantation are necessary; centralization of these children may be helpful to achieve better outcomes than currently observed.

Identifiants

pubmed: 31410937
doi: 10.1111/petr.13569
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13569

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Davenport M, Ville de Goyet J, Stringer MD, et al. Seamless management of biliary atresia. England & Wales 1999-2002. Lancet. 2004;363:1354-1357.
Kasahara M, Umeshita K, Sakamoto S, Fukuda A, Furukawa H, Uemoto S. Liver transplantation for biliary atresia: a systematic review. Pediatr Surg Int. 2017;33:1289-1295.
Nio M. Japanese Biliary Atresia Registry. Pediatr Surg Int Rev. 2017;33:1319-1325.
Pakarinen MP, Johansen LS, Svensson JF, et al. Outcomes of biliary atresia in the Nordic countries - a multicenter study of 158 patients during 2005-2016. J Pediatr Surg. 2018;53:1509-1515.
Chardot C, Buet C, Serinet MO, et al. Improving outcomes of biliary atresia: French national series 1986-2009. J Hepatol. 2013;58:1209-1217.
Davenport M, Ong E, Sharif K, et al. Biliary atresia in England and Wales: results of centralization and new benchmark. J Pediatr Surg. 2011;46:1689-1694.
Leung DH, Narang A, Minard CG, Hiremath G, Goss JA, Shepherd R. A 10-year United Network for Organ Sharing Review of mortality and risk factors in young children awaiting liver transplantation. Liver Transpl. 2016;22:1584-1592.
van der Doef H, van Rheenen PF, van Rosmalen M, Rogiers X, Verkade HJ; for Pediatric Liver Transplantation Centers of Eurotransplant. Wait-list mortality of young patients with biliary atresia: competing risk analysis of a Eurotransplant registry-based cohort. Liver Transpl. 2018;24:810-819.
Malenicka S, Ericzon BG, Jørgensen MH, et al. Impaired intention-to-treat survival after listing for liver transplantation in children with biliary atresia compared to other chronic liver diseases: 20 years' experience from the Nordic countries. Pediatr Transplant. 2017;21:e12851. Epub 2016 Dec 13.
de Vries W, de Langen ZJ, Aronson DC, et al. Mortality of biliary atresia in children not undergoing liver transplantation in The Netherlands. Pediatr Transplant. 2011;15:176-183.
de Ville de GoyetJ. Living donation for a paediatric liver transplantation: an opportunity to be used in accordance with ethical principles. MEDIC. 2015;23:39-51.
Miller CM, Durand F, Heimbach JK, et al. The International Liver Transplant Society Guideline on living liver donation. Transplantation. 2016;100:1238-1243.
Grimaldi C, di Francesco F, Chiusolo F, et al. Aggressive prevention and preemptive management of vascular complications after pediatric liver transplantation: a major impact on graft survival and long-term outcome. Pediatr Transplant. 2018;22:e13288.
Emond JC, de Ville de GoyetJ. Hepatic venous reconstruction as the stake of the liver: technical note and thoughts. Pediatr Transplant. 2014;18:420-422.
de Ville de Goyet J, di Francesco F, Sottani V, et al. Splitting livers: trans-hilar or transumbilical division? Technical aspects and comparative outcomes. Pediatr Transplant. 2015;19:517-526.
Kasahara M, de Ville de GoyetJ. Reducing left liver lobe grafts, more or less? Don't throw out the baby with the bath water. Pediatr Transplant. 2015;19:815-817.
Nadalin S, Monti L, Grimaldi C, di Francesco F, Tozzi AE, de Ville de Goyet J. Roux-en-Y hepatico-jejunostomy for a left segmental graft: do not twist the loop, stick it! Pediatr Transplant. 2015;19:358-365.
Angelico R, Trapani S, Spada Met al. A National Mandatory-Split Liver Policy: a report from the Italian Experience. Am J Transplant. 2019;12:2029-2043; Epub ahead of print.
McDiarmid SV, Anand R, Martz K, Millis MJ, Mazariegos G. A multivariate analysis of pre-, peri-, and post-transplant factors affecting outcome after pediatric liver transplantation. Ann Surg. 2011;254:145-154.
Broering DC, Kim JS, Mueller T, et al. One hundred thirty-two consecutive pediatric liver transplants without hospital mortality: lessons learned and outlook for the future. Ann Surg. 2004;240:1002-1012.
Englesbe MJ, Pelletier SJ, Kheterpal S, O'Reilly M, Campbell DA. A call for a national transplant surgical quality improvement program. Am J Transplant. 2006;6:666-670.
Englesbe MJ, Kelly B, Goss J, et al. Reducing pediatric liver transplant complications: a potential roadmap for transplant quality improvement initiatives within North America. Am J Transplant. 2012;12:2301-2306.
D'Souza R, Grammatikopoulos T, Pradhan A, et al. Acute-on-chronic liver failure in children with biliary atresia awaiting liver transplantation. Pediatr Transplant. 2019;23:e13339.
Kohaut J, Guérin F, Fouquet V, et al. First liver transplantation for biliary atresia in children: the hidden effects of non-centralization. Pediatr Transplant. 2018;22:e13232. [Epub ahead of print].
Karakoyun M, Baran M, Turan C, Kılıç M, Ergun O, Aydoğdu S. Infants with extrahepatic biliary atresia: effect of follow-up on the survival rate at Ege University Medical School transplantation center. Turk J Gastroenterol. 2017;28:298-302.
Lampela H, Ritvanen A, Kosola S, et al. National centralization of biliary atresia care to an assigned multidisciplinary team provides high-quality outcomes. Scand J Gastroenterol. 2012;47:99-107.
Durkin N, Davenport M. Centralization of Pediatric Surgical Procedures in the United Kingdom. Eur J Pediatr Surg. 2017;27:416-421.
McKiernan PJ, Baker AJ, Lloyd C, Mieli-Vergani G, Kelly DA. British paediatric surveillance unit study of biliary atresia: outcome at 13 years. J Pediatr Gastroenterol Nutr. 2009;48:78-81.
Sundaram SS, Mack CL, Feldman AG, Sokol RJ. Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care. Liver Transpl. 2017;23:96-109.
Tessier ME, Harpavat S, Shepherd RW, et al. Beyond the Pediatric end-stage liver disease system: solutions for infants with biliary atresia requiring liver transplant. World J Gastroenterol. 2014;20:11062-11068.
Stringer MD. Biliary atresia: service delivery and outcomes. Semin Pediatr Surg. 2008;17:116-122.
Chardot C, Carton M, Spire-Bendelac N, et al. Is the Kasai operation still indicated in children older than 3 months diagnosed with biliary atresia? J Pediatr. 2001;138:224-228.
Superina R. Biliary atresia and liver transplantation: results and thoughts for primary liver transplantation in select patients. Pediatr Surg Int. 2017;33:1297-1304.
Wang P, Xun P, He K, Cai W. Comparison of liver transplantation outcomes in biliary atresia patients with and without prior portoenterostomy: a meta-analysis. Dig Liver Dis. 2016;48:347-352.
Kitajima T, Sakamoto S, Sasaki K, et al. Living donor liver transplantation for post-Kasai biliary atresia: analysis of pretransplant predictors of outcomes in infants. Liver Transpl. 2017;23:1199-1209.
Shneider BL, Magee JC, Karpen SJ, et al. Total serum bilirubin within 3 months of hepatoportoenterostomy predicts short-term outcomes in biliary atresia. J Pediatr. 2016;170:211-217.
Nakajima H, Koga H, Okawada M, Nakamura H, Lane GJ, Yamataka A. Does time taken to achieve jaundice-clearance influence survival of the native liver in post-Kasai biliary atresia? World J Pediatr. 2018;14:191-196.
Nightingale S, Stormon MO, O'Loughlin EV, et al. Early posthepatoportoenterostomy predictors of native liver survival in biliary atresia. J Pediatr Gastroenterol Nutr. 2017;64:203-209.
Hukkinen M, Kerola A, Lohi J, et al. Treatment policy and liver histopathology predict biliary atresia outcomes: results after National Centralization and Protocol Biopsies. J Am Coll Surg. 2018;226:46-57.
Pugliese R, Fonseca EA, Porta G, et al. Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure. Hepatology. 2014;59:1964-1971.
Bourdeaux C, Darwish A, Jamart J, et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. Am J Transplant. 2007;7:440-447.
Montenovo MI, Bambha K, Reyes J, Dick A, Perkins J, Healey P. Living liver donation improves patient and graft survival in the pediatric population. Pediatr Transplant. 2019;23:e13318.
Mogul DB, Luo X, Bowring MG, et al. Fifteen-year trends in pediatric liver transplants: split, whole deceased, and living donor grafts. J Pediatr. 2018;196:148-153.
Austin MT, Feurer ID, Chari RS, Gorden DL, Wright JK, Pinson CW. Survival after pediatric liver transplantation: why does living donation offer an advantage? Arch Surg. 2005;140:465-470.
Emond J. Reducing complications in pediatric liver transplantation: do we have the answer? Am J Transplant. 2012;12:2267-2268.
Meyers RL, Tiao G, de Ville de Goyet J, Superina R, Aronson DC. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr. 2014;26:29-36.
Kueht M, Thompson P, Rana A, Cotton R, O'Mahony C, Goss J. Effects of an early referral system on liver transplantation for hepatoblastoma at Texas Children's Hospital. Pediatr Transplant. 2016;20:515-522.
Ezekian B, Mulvihill MS, Schroder PM, et al. Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma. Pediatr Transplant. 2018;22:e13305.

Auteurs

Jean de Ville de Goyet Prof (J)

Department for the Treatment and Study of Pediatric Abdominal Diseases and Abdominal Transplantation, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Via E. Tricomi, Palermo, 90127, Italy.

Chiara Grimaldi (C)

Department of Surgery, Abdominal Transplantation and Hepatobiliopancreatic Surgical Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.

Fabio Tuzzolino (F)

Research Office, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Palermo, Italy.

Fabrizio di Francesco (F)

Department for the Treatment and Study of Pediatric Abdominal Diseases and Abdominal Transplantation, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Via E. Tricomi, Palermo, 90127, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH